161 related articles for article (PubMed ID: 33272036)
1. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.
Bairey Merz CN; Handberg EM; Shufelt CL; Mehta PK; Minissian MB; Wei J; Thomson LE; Berman DS; Shaw LJ; Petersen JW; Brown GH; Anderson RD; Shuster JJ; Cook-Wiens G; Rogatko A; Pepine CJ
Eur Heart J; 2016 May; 37(19):1504-13. PubMed ID: 26614823
[TBL] [Abstract][Full Text] [Related]
5. Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
Tagliamonte E; Rigo F; Cirillo T; Astarita C; Quaranta G; Marinelli U; Caruso A; Romano C; Capuano N
Echocardiography; 2015 Mar; 32(3):516-21. PubMed ID: 25041234
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
[TBL] [Abstract][Full Text] [Related]
7. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction ancillary study.
Rambarat CA; Elgendy IY; Handberg EM; Bairey Merz CN; Wei J; Minissian MB; Nelson MD; Thomson LEJ; Berman DS; Shaw LJ; Cook-Wiens G; Pepine CJ
Int J Cardiol; 2019 Feb; 276():8-13. PubMed ID: 30293664
[TBL] [Abstract][Full Text] [Related]
8. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
9. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
10. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
11. ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial.
Sinha A; Rahman H; Douiri A; Demir OM; De Silva K; Clapp B; Webb I; Gulati A; Pinho P; Dutta U; Ellis H; Shah AM; Chiribiri A; Marber M; Webb AJ; Perera D
Circulation; 2024 Jan; 149(1):36-47. PubMed ID: 37905403
[TBL] [Abstract][Full Text] [Related]
12. Ranolazine reduces repolarization heterogeneity in symptomatic patients with diabetes and non-flow-limiting coronary artery stenosis.
Evaristo E; Stocco FG; Shah NR; Cheezum MK; Hainer J; Foster C; Nearing BD; Di Carli M; Verrier RL
Ann Noninvasive Electrocardiol; 2018 Jan; 23(1):. PubMed ID: 28653394
[TBL] [Abstract][Full Text] [Related]
13. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Subjective Well-Being by Ranolazine in Patients with Chronic Angina and Known Myocardial Ischemia (IMWELL Study).
Bavry AA; Park KE; Choi CY; Mahmoud AN; Wen X; Elgendy IY
Cardiol Ther; 2017 Jun; 6(1):81-88. PubMed ID: 28044265
[TBL] [Abstract][Full Text] [Related]
15. Angina relates to coronary flow in women with ischemia and no obstructive coronary artery disease.
Suppogu N; Wei J; Quesada O; Shufelt C; Cook-Wiens G; Samuels B; Petersen JW; Anderson RD; Handberg EM; Pepine CJ; Bairey Merz CN
Int J Cardiol; 2021 Jun; 333():35-39. PubMed ID: 33662486
[TBL] [Abstract][Full Text] [Related]
16. Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris.
Willis LH; Slentz CA; Johnson JL; Kelly LS; Craig KP; Hoselton AL; Kraus WE
Am J Cardiol; 2019 Sep; 124(5):655-660. PubMed ID: 31296368
[TBL] [Abstract][Full Text] [Related]
17. Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial.
Sidik NP; Stanley B; Sykes R; Morrow AJ; Bradley CP; McDermott M; Ford TJ; Roditi G; Hargreaves A; Stobo D; Adams J; Byrne J; Mahrous A; Young R; Carrick D; McGeoch R; Corcoran D; Lang NN; Heggie R; Wu O; McEntegart MB; McConnachie A; Berry C
Circulation; 2024 Jan; 149(1):7-23. PubMed ID: 37795617
[TBL] [Abstract][Full Text] [Related]
18. Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial.
Birkeland K; Khandwalla RM; Kedan I; Shufelt CL; Mehta PK; Minissian MB; Wei J; Handberg EM; Thomson LE; Berman DS; Petersen JW; Anderson RD; Cook-Wiens G; Pepine CJ; Bairey Merz CN
JMIR Res Protoc; 2017 Dec; 6(12):e255. PubMed ID: 29263019
[TBL] [Abstract][Full Text] [Related]
19. Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1-Year Follow-Up: Results From WISE-CVD.
Quesada O; Hermel M; Suppogu N; Aldiwani H; Shufelt C; Mehta PK; Cook-Wiens G; Maughan J; Berman DS; Thomson LEJ; Handberg EM; Pepine CJ; Bairey Merz CN; Wei J
J Am Heart Assoc; 2020 Jul; 9(13):e016305. PubMed ID: 32578481
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial.
Mehta PK; Sharma S; Minissian M; Harsch MR; Martinson M; Nyman JA; Shaw LJ; Bairey Merz CN; Wenger NK
J Womens Health (Larchmt); 2019 May; 28(5):573-582. PubMed ID: 30888919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
